{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', 'Secondary and exploratory efficacy endpoints will be summarized and listed.', 'The between-treatment comparisons will be performed for the combined analysis with', 'Study BCX7353-302 using a similar negative binomial regression model for the investigator- or', 'expert-confirmed angioedema events during the effective treatment period.', 'The between-treatment comparison for the responder endpoints will be performed using', \"Cochran-Mantel-Haenszel, Chi-square, or Fisher's exact test. Multiplicity adjustments for the\", 'secondary endpoints are described in Section 13.1.3.', 'Additional related details of angioedema events (eg, symptoms, anatomical location,', 'hospitalizations, emergency room visits, and angioedema event duration) will be summarized', 'and listed. Details of these analyses will be provided in the SAP.', 'The efficacy endpoints for Parts 2 and 3 include:', 'Number and rate of angioedema events', 'Durability of response (angioedema event rate trend over time)', 'Number and proportion of days with angioedema symptoms', 'Use of medications to treat angioedema events', 'Discontinuations due to lack of efficacy (through Week 52 [Part 2] only)', 'Durability in AE-QoL questionnaire scores', 'Durability in EQ-5D-5L scores', 'Durability in TSQM scores', 'Durability in WPAI scores', 'The analyses of efficacy for Parts 2 and 3 will be provided for the current study. For the placebo', 'subjects who switched to an active BCX7353 dose, the change from placebo to the active dosing', 'period will be summarized. Details of the planned efficacy analyses for the entire study will be', 'provided in the SAP.', '13.4.5.', 'Planned Analyses', 'The primary analysis is planned after the last subject completes the 24 weeks of study (last', 'subject completes Part 1).', 'The investigators, study staff, and subjects will remain blinded until after the database has been', 'locked and the final analysis conducted. The final analysis will occur after the last subject', 'completes 52 weeks of study. Analysis of the 52-week data will be comprised of data from the', 'current study alone.', '13.4.6.', 'Analysis of Safety Variables', 'Analysis of safety data will be conducted for the current study alone.', 'The safety analyses will be analyzed separately for Part 1 alone; a later data analysis will', 'evaluate long-term safety data for the current study.', '99']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', 'Safety endpoints that will be summarized include, at a minimum, the number and proportion of', 'subjects: 1) with a TEAE; 2) who discontinue BCX7353 due to a TEAE; 3) who experience a', 'TESAE; 4) who experience a treatment-emergent Grade 3 or 4 AE; and 5) who experience a', 'treatment-emergent Grade 3 or 4 laboratory abnormality. In addition, the proportion of subjects', 'with a treatment-emergent, treatment-related AE consistent with a drug rash as identified by the', 'investigator will also be summarized.', 'Adverse events will be mapped to a Medical Dictionary for Regulatory Activities (MedDRA)', 'preferred term and system organ class. The occurrence of TEAEs will be summarized using', 'MedDRA preferred terms, system organ classifications, and severity. Separate summaries of', 'TEAEs, TESAEs, AEs considered to be related to study drug, and AEs leading to study drug', 'interruption will be generated. All AEs will be listed for individual subjects showing both', 'verbatim and preferred terms.', 'Descriptive summaries of vital signs, weight, bedside ECG parameters, and clinical laboratory', 'results will be presented. Laboratory abnormalities will be graded according to the DMID Adult', 'Adverse Event Table (Publish Date: Draft, November 2007; Appendix 16.1).', 'Any graded abnormality that occurs following the initiation of study drug and represents at least', 'a 1-grade increase from the baseline assessment is defined as treatment emergent. The number', 'and percentage of subjects experiencing treatment-emergent graded toxicities will be', 'summarized. Laboratory toxicity shifts from baseline to worst postbaseline assessments will be', 'summarized.', 'Clinically significant abnormal morphological ECG findings will be summarized.', 'The change from baseline in QTcF will be determined by routine ECGs. At each time point', \"ECGs are analyzed, an individual subject's change from baseline will be calculated as:\", 'Aik= (QTcF for subject at time point k - Baseline QTcF)', 'Where QTcF measurements will be the average of triplicate ECGs at baseline and single values', 'at each time point.', 'For routine ECGs, the number and proportion of subjects with QTcF 450, > 450 to 480,', '> 480 to 500, and > 500 msec; or changes of VI 30, > 30 to 60, or > 60 msec will be', 'summarized.', 'Physical examination findings will be listed.', 'Concomitant medications will be coded using the World Health Organization drug dictionary', 'and summarized.', 'As applicable, safety data will be summarized by treatment group and total BCX7353.', 'No tests of hypotheses are planned for safety data.', '13.4.7.', 'Health Outcome Analyses', 'Health outcome endpoints are as follows:', 'Durability in TSQM scores', 'Durability in WPAI scores', '100']\n\n###\n\n", "completion": "END"}